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Summary 
The relationship between the characterized mouse regulators of complement activation (RCA) 
genes and the 190-kD mouse complement receptor 1 (MCK1), 155-kD mouse complement receptor 
2 (MCR2), and mouse p65 is unclear. One mouse RCA gene, designatedMCR2 (or Cr2), encodes 
alternatively  spliced  21  and  15  short  consensus  repeat  (SCR)-containing  transcripts  that 
crosshybridize with cDNAs of both human CR2 and CR1, or CR2 alone, respectively. A five 
SCR-containing transcript derived from a second unique gene, designated Crry, also crosshybridizes 
with human CR1. We have previously shown that the 155-kD MCR2 is encoded by the 15 
SCR-containing transcript.  To analyze the protein products of the other transcripts,  which are 
considered  the  genetic homologues of human CRI,  we have  expressed  the  21  and the  5 
SCR-containing cDNAs in the human K562 erythroleukemia cell line. We demonstrate that 
cells expressing the 21 SCK transcript express the 190-kD MCR1 protein. These cells react with 
five unique rat anti-MCR1 monodonal antibodies, including the 8C12 antibody considered to 
be monospecific for MCK1. In addition, these cells efficiently form rosettes with mouse C3b- 
bearing sheep erythrocytes.  In contrast, cells expressing the five SCR-containing Crry transcript 
are strongly recognized by an anti-human CR1 antibody that also defines the mouse p65 protein. 
Using a functional assay that measures the surface deposition of C3 activated via the classical 
complement pathway, we show that Crry/p65-expressing cells have a markedly decreased amount 
of C3 deposited on them as compared with control cells expressing the antisense construct or 
cells expressing MCR1 or MCR2. This suggests that Crry has intrinsic complement regulatory 
activity. Overall,  these studies demonstrate that mouse has an RCA gene family that encodes 
proteins with similar activities and biologic roles, as compared with their human counterparts, 
but with very unique structures. 
T 
he complement system protects an individual against for- 
eign organisms and antigens by promoting chemotaxis 
and  phagocytosis,  increasing  the  lysis and  clearance  of 
pathogens, and participating in the trafficking of immune 
complexes through the circulation (reviewed in reference 1). 
While this system is highly effective, it has also been recog- 
nized that activated complement fragments have the capacity 
to bind and attack sdf tissues, especially in areas of active 
inflammation. To protect autologous bystander ceUs from the 
ddeterious effects of complement, several membrane-bound 
and serum proteins have evolved in humans. These proteins 
interact with the complement cascade and, by inactivating 
its convertase enzymes,  are believed to protect  self tissue 
(reviewed in references 2-6). 
Four complement receptor and regulatory proteins  are 
present on the surface of human cells and interact with com- 
plement component C3, an essential participant in this system. 
These proteins are encoded by the regulators of complement 
activation  (RCA) 1 gene family located on the long arm of 
chromosome 1 (7-9). Includecl in this RCA family is human 
1 Abbreviations used in this paper: DAF, decay-accelerating  factor;  MCP, 
membrane cofactor protein; KCA, regulators of complement activation; 
SCK, short consensus  repeat. 
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CR1 also acts as a cofactor for factor I-mediated C3b and 
C3bi cleavage and subsequently inactivates the convertase con- 
taining this molecule. Human CR1 also accelerates decay of 
the C3 convertases. Membrane cofactor protein (MCP), an- 
other family member, is an integral membrane glycoprotein 
found on a wide variety of calls that also has cofactor activity 
for factor I-mediated C3b cleavage. Deeay-accderating factor 
(DAF), a third member, is a glycolipid-anchored  protein that 
both inhibits the formation of and accelerates the decay of 
the C3 convertases. The fourth member, human CR2, has 
been reported to act as a cofactor for factor I-mediated cleavage 
of C3bi in addition to serve as a receptor for C3d,g and the 
EBV. 
Several investigators have analyzed mouse counterparts of 
the human RCA family using ligand binding, immunochem- 
ical, and molecular hybridization techniques. Three proteins 
that bind mouse C3-Sepharose  have been identified on the 
membrane of murine splenocytes (10, 11). The largest, a 190- 
kD protein designated mouse CK1 (MCR1), has receptor 
activities  and mediates rosette formation with mouse C3b- 
coated sheep erythrocytes. In addition, MCK1 demonstrates 
regulatory functions that resemble human CR1 in that it serves 
as a fluid phase cofactor for factor I-mediated cleavage  of mouse 
C3b and C3bi (10). 
The second largest C3-Sepharose binding protein, 155 kD, 
is believed to be the mouse homologne of human CR2. This 
protein, designated MCR2 (or Cr2), mediates rosette for- 
mation with mouse C3d=coated erythrocytes (12) and is en- 
coded by a gene within the mouse RCA locus (13-16) that 
has extensive similarity to the human CR2 gene (16). This 
conclusion is substantiated by the observation that expres- 
sion of a 15 short consensus repeat (SCR)--containing cDNA 
derived from this gene results in a protein with identical Mr 
and activities as compared with the 155=kD splenic MCR2 
protein (17). Of interest, four of five mAbs directed against 
the 190-kD MCR1 protein also react with the 155-kD MCR2 
(10-12,  16, 17). A 21 SCR-containing alternatively  spliced 
transcript has also been found to be derived from the MCR2 
gene, and the 190-kD MCR1 has been proposed to arise from 
this transcript (14). However,  this has not been previously 
formally demonstrated. 
Recently, a 60-kD membrane protein with DAF-like prop- 
erties has been isolated from mouse erythrocytes; however, 
the sequence of its protein and gene, in addition to its ca- 
pacity to bind C3-Sepharose,  is unknown (18). No genetic 
DAF or MCP homolognes have been yet found in mice de- 
spite attempted identification by cross-species hybridization 
techniques (15; V. M. Holers, unpublished observations;  and 
J.  p. Atkinson, personal communication). 
A third mouse spleen cen guinea pig C3b-Sepharose binding 
protein, p65, has been characterized due to its ability to cross- 
react with a polyclonal rabbit anti-human CR1 antiserum 
(19). p65 is widely distributed, present on murine spleno= 
cytes, lymph node cells, peritoneal macrophages, erythrocytes, 
and L929 ceils. Although p65 binds to guinea pig C3b= 
Sepharosr  the physiologic function of p65 has been undefined. 
In addition, its relationship to p60, the third mouse C3- 
Sepharose binding protein (10), and Crr/,,  a human CRI 
genetic homologue, has been unclear.  The Crry gene was 
identified in mice by hybridization studies using human CRI 
probes against mouse genomic and cDNA libraries (20-23). 
Crry has been reported to encode a 70=kD protein consisting 
of a signal peptide, five SCRs,  a transmembrane, and in- 
tracytoplasmic domain. Although similar to areas of human 
CR1 in its sequence,  the broad tissue distribution of Crry 
transcripts has suggested that the Crry protein does not have 
comparable C3 receptor functions. The function of the Crry 
gene product, or indeed its relationship to the complement 
pathway, has been unknown. 
To further understand the interelationships between the 
mouse genetic and functional homolognes of human RCA 
proteins, we have undertaken to express and analyze recom- 
binant forms of each homologous mouse cDNA. Herein we 
report our analysis of recombinant MCRI and recombinant 
Crry, both of which contain sequences that hybridize to human 
CRI cDNA probes and are, therefore, considered to be genetic 
homologues of human CR1. We demonstrate that the 190- 
kD MCR1 is encoded by the 21 SCR-containing alterna- 
tively spliced transcript arising from the MCR2 (Cr2) gene 
and that the previously described protein, I)65, is encoded 
by the Crry gene. In addition, we show that cells expressing 
the Crry/p65 protein are remarkably protected from classical 
pathway-mediated complement attack  as  measured by  a 
significant decrease in mouse C3 deposition on their surface. 
This intrinsic regulatory activity is in contrast to calls ex- 
pressing either MCR1 or MCR2. Overall, these studies show 
that Crry/p65 has important complement regulatory activi- 
ties and that in mice, a unique set of proteins has evolved 
that act  as C3 receptors and that protect self tissue from 
complement-mediated damage. 
Materiah and Methods 
Cloning and Expression of  MCR1 and Crry cDNAs,  By primer 
extension and PCR-based methods using RNA from BALB/c 
splenocytes,  we obtained a cDNA containing the initial six SCRs 
of the previously  described  21 SClk--cuntaining  transcript encoded 
by the MCR2 gene (14). This partial cDNA was cloned into the 
5' portion of our 15 SCR--containing  plasmid pBSMCR2-5 (16, 
17) to obtain the full-length 21 SCK-containing cDNA. To ex- 
press the Crry transcript, we used a cDNA that we had previously 
isolated (23) from a BALB/c  peritoneal macrophage  cDNA library 
cloned into )~gtl0 and screened  with a partial human CR1 cDNA 
(24). This clone was sequenced  and shown to be essentially  iden- 
tical to the nonintervcning sequence  containing Crry cDNA (20). 
An EcoRI site near the 3' end was altered  by PCR-based mutagen- 
esis without changing the predicted  protein sequence.  Both cDNAs 
were cloned  into the pSFFV-neo  plasmid  in sense  or antisense  orien- 
tations and transf~cted by dectroporation into the human K562 
erythroleukemia  cell  line using previously  described  t~hniques (25). 
Preparation and Characterization  of  Antibodies.  Anti=KS62  poly- 
clonal antibody was prepared by emulsification of 10  a wild-type 
K562 cells with Freund's adjuvant followed by serial immuniza- 
tion of New Zealand rabbits. The immune antiserum was assayed 
by flow cytometry and rabbit complement-mediated  cellular  cyto- 
toxicity to assure its anti-KS62 reactivity. Immunoglobulins from 
the reactive  antiserum were isolated  by ammonium sulfate precipi- 
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antiserum was the same reagent used in previous studies (19). The 
rabbit polyclonal anti-human DAF antiserum and the murine mAb 
to human MCP, TRA-2-10(26, 27), were generously provided by 
T. Oglesby and J.P. Atkinson (Washington University School of 
Medicine, St. Louis, MO). 7E9, 7G6, 8C12, 4E3, and 8D9 are rat 
anti-MCR1 mAbs (11, 12), and BRN-1 is a rabbit polyclonal an- 
tiserum raised  against  a fusion protein expressing  10 SCRs of 
MCR2 (16). 
Flow  Cytometric  Analysis.  106 K562 cells  expressing recom- 
binant Crry (rCrry) in sense or antisense orientations were incubated 
at 4~  in 25 #1 of HBSS containing 1% human serum albumin 
with 120 #g/ml of nonimmune rabbit F(ab')z (Cappel Laborato- 
ties,  West  Chester,  PA)  or affauity-purified  rabbit F(ab')z anti- 
human CK1/p65 as a first-step antibody. After 60 rain, cells were 
washed,  and  FITC-conjugated  goat  F(ab')z  anti-rabbit  F(ab')z 
(Cappel Laboratories) was added. After a 60-rain incubation and 
washes,  cells were analyzed by flow cytometry on a FACScan  | 
(Becton Dickinson & Co., Palo Alto, CA). 
Analysis of DAF and MCP expression was performed by using 
106 cells in a buffer containing PBS, 1.0% BSA, and 0.02% NAN3. 
First-step antibodies included equal amounts of either nonimmune 
rabbit serum or immune rabbit anti-DAF serum, and 7 #g each 
of MOPC-21 (Sigma Chemical Co., St. Louis, MO) or anti-MCP 
mAb. FITC-conjugated goat F(ab')2 anti-rabbit  Ig (Cappel Labora- 
tories) or anti-mouse Ig (Cappel Laboratories) were used as second- 
step antibodies.  Analysis  of recombinant MCR1  (rMCR1)  and 
MCR2 (rMCK2) expression was performed by using 1 #g of the 
rat anti-MCK1 mAb. FITC-conjugated goat anti-rat Ig (Cappel 
Laboratories) was used as the second-step antibody. 
Iramunotnrcipitation  and SDS-PAGE  Analysis.  K562 cells ex- 
pressing rMCK1 and BALB/c splenocytes were surface labeled with 
mI and solubilized using PBS containing 1% NP-40 and protease 
inhibitors as previously described (16). Solubilized cell preparations 
were incubated either with preimmune or immune BKN-1 serum. 
The immune complexes were collected using protein A-Sepharose 
(Pharmacia, Uppsala, Sweden) and washed four times with PBS/1% 
NP-40.  Pellets  were treated with SDS-PAGE  sample buffer and 
heated to 85~  for 5 min. Eluted samples were analyzed by 7.5% 
SDS-PAGE. 
Erythrocyte Rosette  Formation.  Sheep erythrocytes (E) bearing 
complement components were prepared as previously described to 
obtain reagents bearing forms of either human (28) or mouse (12) 
C3. For analysis, 1.5  x  10  s K562 cells expressing sense orienta- 
tion rMCK1, sense orientation rMCK2, sense or antisense orien- 
tation rCrry, or wild-type K562 cells in 100 #1 PBS were incubated 
in 50 #1 of HBSS with 1% human serum albumin,  2 mM MgCI2, 
and 0.15 mM CaClz. The cells and Es were gently mixed, cen- 
trifuged at 500 rpm for two min at 4~  and incubated for 20 
rain at 37~  Cells with three or more adherent Es were scored 
as positive. To test the effect of mAbs on E-rosette formation, cells 
were preincubated with 10 #g/ml of antibody for 15 rain at room 
temperature before E addition. 
Detection of C3 Deposition.  l& cells in 100 #1 of KPMI con- 
taining 2 mM MgC12 and 0.15 mM CaClz, or 2 mM MgC12 and 
10 mM EGTA, were incubated with 100/zg of purified rabbit anti- 
K562 polyclonal antibody and 20 #1 (see Figs. 4 and 5) or increasing 
amounts (see Fig. 6) of BALB/c mouse serum, or equal amounts 
of heat inactivated BALB/c mouse serum obtained at the same 
bleeding. Incubation was performed at 37~  for 60 min. After 
washing with PBS containing 1.0% BSA, the cells were analyzed 
for the presence of mouse (23 on their surface by a variation of 
a  previously  described  technique  (29).  FITC-conjugated  goat 
anti-mouse C3 antibody (Cappel Laboratories) was added at 4~ 
for 30 rain followed by washing and flow cytometry as above. Heat 
inactivation of the routine serum was performed at 56~  for 60 
min. In preliminary experiments using StCr-labded  K562 cells, all 
of these conditions were shown to be noncytotoxic. 
Results 
Expression of rCrry.  Nucleotide sequence analysis of our 
Crry cDNA revealed it to be almost identical to the sequence 
of Paul et al.  (21), containing a signal peptide,  five SCKs, 
a transmembrane, and an intracytoplasmic region. Slight differ- 
ence noted were the presence of a GC instead of a CG at 
nucleotides 537 and 538 (21), changing a single amino acid 
from alanine to glycine in the area of the signal peptide, and 
a C  instead of a G  at nucleotide 965, changing a glutamic 
acid to glutamine within the first intercysteine region of the 
second SCR. We subcloned this cDNA into the eukaryotic 
expression vector pSFFV-neo and stably transfected it into 
the human K562 erythroleukemia cell line. 
Although the identity of the protein encoded by the Crry 
transcript was unknown,  we believed that it might be the 
previously described p65 (19). To test this hypothesis, we ana- 
lyzed by flow cytometry our rCrry-expressing K562 cells using 
the affinity purified  F(ab')z anti-human CR1/p65,  which 
specifically  recognizes p65 on the surface of murine cells. This 
antibody does not immunoprecipitate the 190-kD MCK1 or 
the 155-kD MCR2 proteins. Flow cytometric analysis of stable 
lines obtained from transfection  with the rCrry sense and 
antisense constructs are shown in Fig.  1. Cells transfected 
with the sense orientation construct react strongly with the 
anti-human CK1/p65 antibody,  as compared with the an- 
tisense transfected control (Fig.  1 A). No specific staining 
of either cell population is detected with the nonimmune 
rabbit F(ab')2 control (Fig. 1 B). Three separate transfections 
gave identical results. As a further control, no human CK1 
is expressed by these transfected cells, as assessed by the lack 
of staining with the anti-human CR1 mAb 3D9 (data not 
shown). These results demonstrate that Crry encodes the p65 
protein. 
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Figure 1.  (.4)  Flow cytometric  analysis  demonstrating expression  of  p65 
by rCrry sense orientation constructs (solid line), but not antisense con- 
structs (dotted line), in K562 cells as detected by anti-human CR1/p65 
antibody, x-axis is relative  fluorescence  on a log scale;  ),-axis is cell number. 
(/3) Flow cytometric analysis demonstrating lack of reactivity of cells ex- 
pressing either rCrry sense (solid line) or antisense (dotted line) constructs 
with control antibody. 
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Figure 2.  Flow cytometric analysis using five different rat anti-MClkl 
antibodies on K562 cells expressing rMCR1 (solid line), rMCR2 (dashed 
line), or the rMCR1 antisense comtruct (dotted  line), x-a.,ds is rehtive fluores- 
cence on a log scale; y-axis is cell number. 
Expression of the 21 SCR Containing MCR2 (Cr2) Gene-de- 
rived Transcript  (rMCRI~  The cDNA we cloned and expressed 
is essentially identical to the alternative  21 SCtk--containing 
transcript derived from the MCR2 (Cr2) gene as described 
by Kurtz et al.  (14). Differences noted are an A instead of 
a C nucleotide 336, which does not change the amino acid 
sequence, A second difference is the absence of one complete 
codon, AGC, beginning at nucleotide 541 of the Kurtz se- 
quence. This triplet encodes a serine in the first intercysteine 
region in the third SCR of the mature protein. The nature 
of this difference is currently unknown; however, there ap- 
pears to be no significant functional or antigenic consequence 
(see below). 
After subdoning this cDNA into pSFFV-neo and expressing 
it in the K562 cell line, we analyzed its relationship to the 
190-kD MCR1 protein. As shown in Fig. 2, flow cytometric 
analysis reveals that ceUs transfected with the sense orienta- 
tion construct are recognized by five rat mAbs raised against 
MCR1, including the mAb 8C12 (Fig. 2 C). Four of these 
mAbs also react with MCR2; however, 8C12 is monospecific 
for MCR1. Indeed, ceils transfected with rMCR2 are stained 
by all mAbs except 8C12 (17, and Fig. 2 C). Ceils transfected 
with the antisense construct of the 21 SCR containing tran- 
script and wild-type K562 cells are not recognized by any 
of the mAbs. In addition, the rMCR1- and rMCR2-cxpt~sing 
cells are not stained by the anti-human CR1/p65 antibody 
to a detectable  level by flow cytometry (data  not shown). 
To further demonstrate that MCR1 is encoded by the 21 
SCR-containing transcript, we performed an immunopre- 
cipitation analysis using BRaN-l, a rabbit polyclonal antiserum 
raised against MCR2 that also immunoprecipitates MCR1 
(16).  As shown in Fig.  3,  BRN-1  recognizes the 190-kD 
MCR1 and the 155-kD MCR2 proteins from a mouse spleen 
lysate. Only the 190-kD  protein is immunoprecipitated by 
BRN-1 from the cells transfected with the 21 SCR cDNA. 
The Mr under both reducing and nonreducing conditions is 
essentially identical to spleen cell-derived MCR1. Pre-immune 
serum fails to react with either of these two proteins in the 
spleen or in the transfected  cell populations. 
Ewthrocyte Rosette Formation.  Previous experiments have 
shown that primary spleen cells and cell lines expressing MCR1 
are able to form rosettes with Es bearing the mouse C3b frag- 
ment and that this reaction is partially inhibited by the mAb 
8C12. We used this information to analyze the activities of 
our rMCRl-expressing K562 cells. As shown in Table 1, these 
Figure 3.  Autoradiograph of 7.5% 
no.reducing (/eft) and reducing (right) 
SDS-PAGE of surface-labeled and soh- 
bilized K562  ceils  expressing  either 
rMCR1  (lanes  1,  2,  5,  and  6),  or 
BALB/c spleen ceUs (lanes 3, 4, 7, and 
8),  immunopreeipitated with  preim- 
mune (lanes 1,3, 5, and 7) or immune 
(lanes 2, 4, 6, and 8) serum from rabbit 
BRN-1. (Arrows) The specific 190-kD 
MCR1 band. 
124  Mouse Homologues of Human  Complement Receptor 1 Table  1.  E Rosette Formation Mediated by Recombinant Molecules 
Cells 
rMCR1  rMCR2  rCrry  rCrry 
Erythrocytes  (sense)  (sense)  (sense)  (antisense)  K562 
EAC142  4  1  -*  -  1 
EAC1423b  67  32  4  6  3 
EAC1423d  15  64  1  2  1 
EAC3b  +  8C12  42  29  -  -  - 
EAC3b  +  7G6  18  1  -  -  - 
EAC3b  +  7E9  65  31  -  -  - 
EAC3b  +  total rat  Ig  60  .... 
EAC3d  +  8C12  10  67  -  -  - 
EAC3d  +  7G6  0  0  -  -  - 
EAC3d  +  7E9  19  75  -  -  - 
EAC3d  +  total rat Ig  14  .... 
percent cells forming rosettes with sheep erythrocytes bearing complement components as noted (human C4b and mouse C3b or C3d), and effect 
of three mAbs or total rat lg on rosette formation.  Results shown for rMCR1 and rMCR2 were performed at the same time, are representative 
of many experiments, and were calculated based on ~ 300 cells counted per condition. Results using rCrry are derived from one experiment based 
on ;~ 300 cells counted per condition. 
* ND. 
cells are able to efficiently form rosettes with mouse C3b- 
bearing Es.  These rosettes  are partially inhibited  by 8C12. 
In addition, rMCKl-expressing cells also rosette with mouse 
C3d-bearing Es,  although  the relative ability is diminished 
when  compared with rMCK2.  This reaction is totally in- 
hibited  by  7G6,  a  mAb  that  completely  inhibits  C3d- 
dependent rosette formation with B cell lines and rMCK2- 
expressing cells (12,  17).  7G6 also partially inhibits  rosette 
formation between rMCK1 and Es bearing mouse C3b. 7E9, 
another rat mAb that does not possess rosette inhibition ac- 
tivity,  and  total rat  Ig serve as control  antibodies.  As also 
450. 
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Figure 4.  Measurement by flow cytometry of mouse C3 deposition on 
K562 cells transfected  with the rCrry antisense construct. Cells were treated 
either with rabbit anti-K562 antibody alone (dotted line), 20/zl of mouse 
serum alone (thin solid line), anti-K562 antibody plus mouse serum (thick 
solid line), or anti-K562 antibody plus heat inactivated mouse serum (dashed 
line) in either media containing Ca2+/Mg 2+  (A) or media containing 
Mg  2+/EGTA (B). x-axis is relative fluorescence on a log scale; y-axis is 
cell number. 
shown in Table 1, rMCR2-expressing cells rosette with mouse 
C3b-bearing  Es with  a lower efficiency as compared with 
rMCR1,  mAb 7G6, but not 8C12,  inhibits the rosette for- 
mation between  rMCR2  cells and  C3b-bearing  Es. 
These results parallel and are entirely consistent with results 
using spleen cells and cell lines expressing MCR1 and MCR2 
(10-12). They suggest that the C3d binding portion of MCR1 
is still able to interact with C3d in spite of the extra six SCRs, 
that the C3d binding site on MCR2 also interacts with mouse 
C3b,  albeit  with  a  lower overall affinity,  and  that  there is 
an extra C3b binding site in the additional  six SCRs found 
in MCR1. Also of some interest is the finding that rMCR1- 
expressing cells are unable to efficiently form rosettes with 
human  C4b-bearing  Es. 
We also analyzed the ability of rCrry-expressing cells to 
form rosettes with Es bearing these complement components 
(Table  1).  Interestingly,  although  solubilized  p65  has been 
shown to bind guinea pig C3b-Sepharose, no significant for- 
mation of rosettes was detected with mouse C3b-coated Es. 
This confirms previous observations using cell lines bearing 
native p65  (19). 
Control of Mouse C3 Deposition.  We have developed a quan- 
titative assay that measures mouse C3 deposition on the sur- 
face of cells as a marker of complement activation.  In this 
assay cells are treated with a specific rabbit polyclonal anti- 
body, forming a complement-activating immune complex, 
and mouse serum  as the  source of complement.  As Fig.  4 
A  shows, K562 cells expressing the antisense construct treated 
with an anti-K562 polyclonal antibody in addition to 20 #1 
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Figure 5.  Measurement by flow cytometry of mouse C3 deposition on 
K562 cells expressing the rCrry antisense construct (A), rCrry (B), rMCR1 
(C), or rMCR2 (D). Cells were treated with anti-K562 antibody alone 
(dotted line),  anti-K562 antibody plus 20 #1 of mouse serum (solid line), 
or anti-K562 antibody plus heat-inactivated mouse serum (dashed line). 
x-axis is relative fluorescence  on a log scale; y-axis is cell  number. 
of mouse serum demonstrate a greatly increased level of C3 
on their surface as compared with control cells. Controls in- 
dude the same cells treated with the anti-KS62 antibody in 
addition to heat-inactivated mouse serum or cells treated with 
only the anti-K562 antibody. This finding is dependent on 
the presence of Ca  2  § in the media as cells incubated with 
media containing Mg  2  + and EGTA, or media alone, fail to 
stain brightly for mouse C3 (Fig. 4 B). This indicates that 
the classical complement pathway is the major determinant 
of C3 deposition.  A  slight  shift in fluorescence is detected 
in Mg2*/EGTA  medium,  which is probably due to alter- 
native pathway activation.  The deposition of C3 on K562 
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Figure 6.  Comparison of input amount of mouse serum (x-axis) vs. 
C3 deposition as determined by mean channel fluorescence (y-axis) on rCrry- 
expressing cells (open circles) and antisense construct expressing controls 
(open squares). 
cells is dose dependent, begins within the initial 5 rain (data 
not  shown),  and is still stable and present  after 60 min. 
As shown in Fig. 4 A, mouse serum alone is also capable 
of increasing  C3 deposition on these cells, although to a much 
smaller amount as compared with our specific antibody and 
mouse serum combination. This observation is probably due 
to the presence of low affinity naturally occurring mouse an- 
tibody which reacts with the K562 cells and activates com- 
plement.  Consistent  with this,  the reaction can be greatly 
diminished by preabsorbing the sera with K562 cells at 4~ 
before the first-step incubation with the Ca2+/Mg z§  con- 
taining media, and is recovered when we add our specific rabbit 
anti-K562 antibody to the preabsorbed sera (data not shown). 
The presence of p65 in a variety of murine tissues has sug- 
gested a regulatory function for this protein. To test this pos- 
sibility, we measured the deposition of mouse C3 on the sur- 
face of our rCrry-expressing K562 cells, rCrry-expressing cells 
which,  as previously shown in Fig.  1, have a uniform high 
level  expression of p65,  are able to markedly decrease the 
amount of C3 present on the surface of all cells in the popu- 
lation (Fig.  5 B). Cells expressing rMCR1 apparently have 
little if any ability to control the amount of C3 on their sur- 
face as compared with controls (Fig.  5 C). Cells expressing 
rMCR.2 (Fig.  5 D) are also unable to regulate the amount 
of C3 deposition. The markedly lower C3 deposition on rCrry- 
expressing cells is not  due simply to a change in kinetics, 
as analysis of these cells at time points as early as 5 rain does 
not demonstrate C3 deposition at any point (data not shown). 
The effect is seen over a broad range of amounts of added 
mouse serum  (Fig.  6).  As can be seen,  the amount  of C3 
deposition is linear and greatly decreased in rCrry-expressing 
cells.  The effect on complement  activation  is also not due 
to altered levels of human  intrinsic  regulatory proteins,  as 
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Figure  7.  Flow  cytometric 
analysis of MCP  expression on 
transfected  K562  cells,  rCrry 
antisense-expressing  cells  are 
treated  with  7  ttg  of  MOPC 
(dotted line)  or 7 #g of anti-MCP 
mAb (thick line).  Shown also are 
rCrry/p65-eXlnessing cells treated 
with 7/~g of MOPC (dashed line) 
or 7 ttg of anti-MCP mAb (dotted 
and dashed lines),  x-axis is relative 
fluorescence on a log scale; y-axis 
is cell number. 
Figure 8.  Flow cytometric anal- 
ysis  of DAF expression on trans- 
fected  K562 cells, rCrry antisense 
expressing  cells  are  treated  with 
nonimmune rabbit  serum  (dotted 
line)  or immune rabbit anti-DAF 
serum (thick  line).  Shown also  are 
rCrry/p65-expressing cells  treated 
with  nonimmune  rabbit  serum 
(dashed line) or immune rabbit anti- 
DAF sera  (dotted and dashed lines). 
x-axis is relative fluorescence  on a 
log scale; y-axis is cell number. 
126  Mouse Homologues of Human Complement Receptor  1 the levels of human DAF and MCP are identical in the rCrry- 
expressing K562 cells as compared with the rCrry antisense 
construct-expressing K562 cells (Figs.  7 and 8). 
Discussion 
In these studies we have extended our analysis of the mu- 
rine counterparts of human complement receptors and regula- 
tory proteins. Our overall purpose has been to relate genes 
identified as human RCA homologues to characterized mouse 
proteins which bind C3-Sepharose or mediate rosettes with 
mouse C3-coated targets.  In this report, we present direct 
proof that the mouse 190-kD MCR1 protein, which previous 
studies have shown to be the functional homologue of human 
CR1, is encoded by a transcript generated in the mouse CR2 
(Cr2) gene. Our conclusion is based on a number of prin- 
ciples. First, as initially shown by Kurtz et al. (14), the 21 
SCR--containing transcript is derived from this gene. Second, 
our results demonstrate that the protein encoded by this eDNA 
fulfills functional and immunochemical  criteria of the MCR1 
protein. This eDNA-derived protein is recognized by the mAb 
8C12, which is monospecific for the 190-kD mouse C3-Sepha- 
rose binding protein designated MCR1, and has an essen- 
tially identical Mr as the splenic MCR1 protein. In addition, 
it mediates C3b-dependent rosette formation, a reaction that 
is partially inhibited by mAb 8C12. This is the same func- 
tional profile demonstrated by the naturally occurring splenic 
MCR1 protein. Although our results are consistent with a 
MCR1 
12  MCR2 
Crry/p65 
I 
Figure 9.  Schematic representation of mouse membrane RCA proteins 
along with putative sites of antibody reactive. *Intervening sequence present 
in "~10% of Crry/p65 transcripts. 
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second C3 binding site within the first six SCRs of this form, 
expression and analysis of these SCRs alone will be necessary 
to conclusively demonstrate this point. We have also not yet 
assayed the eDNA-encoded protein for fluid phase cofactor 
activity.  However,  as this is an activity that is directly in- 
hibited in the fluid phase by the 8C12 mAb, we believe the 
activity will be retained. 
These results substantiate the principle that both proteins, 
MCR1 and MCR2, are generated by a single transcriptional 
unit. In contrast, humans have distinct nonoverlapping  genes 
for human CR1 and CR2, and the proteins are structurally 
and immunologically distinct. These results also underscore 
the necessity to develop methods of mouse receptor blockade 
that are able in vivo to separate activities  of each receptor. 
It has already been noted that no mAbs to MCR2 are unique 
and that they will also react with and potentially cap or in- 
hibit MCK1. This indicates that the use of soluble receptors 
or peptides will be necessary  to distinguish MCR2 from 
MCR1 function. 
Analysis ofligand specificity by E-rosette studies confirms 
that MCK1 primarily interacts with mouse C3b and MCR2 
with mouse C3d. Of interest, even though MCK1 encodes 
the mouse C3d binding domain contained within the MCR2 
protein, its ability to form rosettes with C3d-coated Es is 
diminished. This effect of masking the C3d binding site may 
allow MCR1 to express a biologic role of primarily inter- 
acting with C3b and not C3d. This would be an interesting 
alternative mechanism that achieves the same relative effect 
as compared with the two separate proteins found in humans. 
In these studies we have also analyzed the second human 
CRI genetic homologue, Crry Several lines of evidence have 
suggested a close relationship between p65 and the Crry eDNA 
gene product. First,  p65 was identified by its crossreaction 
with antiserum raised against human CR1. Second, the Crry 
cDNA is the primary mouse transcript isolated  in experi- 
ments  performed by  hybridization  of mouse eDNA  or 
genomic libraries  with  human  CR1  probes.  The  Crry- 
predicted protein structure has 60-65 % identity with human 
CR1. Both p65 and Crry have been reported to be present 
on a wide variety of murine tissues and have been reported 
to encode membrane bound proteins of 65  and "o70 kD, 
respectively (19, 21). Although p65 and Crry have demon- 
strated these characteristics, no previous studies have directly 
compared the two. 
In these studies, we have stably expressed the Crry eDNA 
on a human K562 erythroleukemia cell line background. The 
sense orientation-transfected cells are specifically and strongly 
recognized by the anti-p65 antibody. It is very unlikely that 
this reaction is not specific to p65, or that the antibody is 
crossreacting with another human RCA protein, because 
repeated transfection of cells with the Crry antisense con- 
struct and selection with neomycin does not result in a cell 
population that stains with this antibody. Moreover, the anti- 
p65  antibody does  not  stain cells  expressing rMCR1  or 
rMCR2. These cells also do not express human CR1, and 
the levels of human DAF and MCP are equivalent between 
the sense and antisense construct-expressing cells. Overall, 
these data constitute the first direct evidence showing that p65 is encoded by the Crry gene. We will now use the desig- 
nation Crry/p65 to reflect these findings. 
To begin to understand the possible functions of Crry/p65 
as a mouse ILCA protein, we have developed an assay that 
quantitates the amount of mouse C3 deposited on the sur- 
face of K562 cells via the classical pathway. Our data demon- 
strate that rCrry/p65-expressing K562 cells are capable of in- 
trinsic complement regulatory activity as manifested by a 
marked decrease in C3 deposition. This inhibition is specific 
to Crry/p65, as MCR1 and MCR2, which are also mouse 
C3 binding proteins, have no apparent significant effect on 
intrinsic C3 deposition. 
Interestingly, MCR1 has fluid phase cofactor activity for 
factor I-mediated cleavage of C3b yet exhibits only minimal 
or no ability to regulate the amount of C3 deposited on the 
MCRl-expressing cells. One likely possible explanation for 
this finding is that this molecule is better suited for extrinsic 
C3 regulation and is more effective in its interaction with 
fluid phase complement components or complement frag- 
ments bound to immune complexes, as has been suggested 
for human CIL1 (30). 
This inhibitory effect of Crry/p65 on intrinsic C3 deposi- 
tion is due to its ability to interact with the early compo- 
nents of the classical pathway. However, the specific molec- 
ular process involved in this regulation is not evident from 
our studies. Also, we have not yet analyzed its ability to block 
alternative pathway-dependent C3 deposition. It is likely that 
Crry/p65 acts to disrupt the C3 convertase.  If the activity 
is similar to that of human DAF or MCP, it will be by the 
process of decay acceleration  or cofactor activity for factor 
I-mediated C3 and/or C4 cleavage. 
Two alternatively  spliced Crry transcripts have been de- 
scribed, with one of them containing an additional 129 bp 
of non-SCR-intervening nudeotide sequence between the 
signal peptide and the first SCR (21). Although identified 
in all murine cells studied, this form is present in a smaller 
amount as compared with the most frequent transcript, which 
we have expressed and which lacks the additional non-SCR 
sequence. The role of this domain is not known, and further 
work is needed to elucidate the functional contribution of 
this region. 
In relation to other candidates for mouse intrinsic mem- 
brane C3 regulatory proteins, the observation that the nucleo- 
tide sequence of Crry/p65 encodes a transmembrane glyco- 
protein suggests that it is not, at least in this form, the mouse 
DAF-like protein described by Kameyoshi et al.  (18). It is 
possible  that  another  as  yet  unidentified  transcriptional 
modification confers upon Crry/p65 a glycolipid anchor; how- 
ever, the available information suggests that this is likely not 
the case. Crry/p65 may also belong to a group of '~,65-kD 
C3 binding proteins found on baboon erythrocytes and rabbit 
macrophages 01-33). However, more information concerning 
these other molecules is needed before establishing their rela- 
tionship to Crry/p65. 
Overall, it is now clearly apparent that mouse has evolved 
some remarkably different KCA genes and proteins to per- 
form the apparently necessary biologic roles of complement 
receptor and intrinsic membrane regulatory protein activi- 
ties. A summary schematic representation of these three pro- 
teins, MCK1, MCK2, and Crry/p65, along with their sites 
of antibody reactivity are shown in Fig. 9. The genetic rela- 
tionships between these genes and their human homologues 
have been extensively discussed (13-17, 20-23). The two pri- 
mary mechanisms proposed to account for the differences in 
gene structures between species are continued evolution facili- 
tated by unequal crossing over of repeat regions and dde- 
tions within the mouse RCA locus. Both mechanisms have 
likely played significant roles in this process. Analysis of the 
RCA locus of other species should prove very informative 
in this regard. 
Finally, both functional blockade and analysis of the ex- 
pression of MCR1, MCIL2, and Crry/p65 in mouse models 
of inflammation should allow an increased understanding of 
the role of these proteins and their receptor or intrinsic mem- 
brane complement regulatory activities  in these processes. 
Analysis of mice with specific ddetions of these genes will 
allow a more complete understanding of their roles in devel- 
opment of the immune system and in specific immune re- 
sponses. 
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